Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NBIP-01435 will be administered per schedule specified in the arm description.”In the company’s words, NCT07850739 on ClinicalTrials.gov
- Tested for
- Congenital Adrenal Hyperplasia
- Main trialPhase 2
- “The main objective of this study is to evaluate the efficacy of different dose levels of NBIP-01435 on reducing elevated androstenedione (A4) levels in adults with classic CAH.”In the company’s words, NCT07850739 on ClinicalTrials.gov
Other drugs for Congenital Adrenal Hyperplasia
- AtumelnantCrinetics Pharmaceuticals Inc. · Phase 3
- CrinecerfontNeurocrine Biosciences · Phase 3
- BBP-631Adrenas Therapeutics Inc · Phase 1/2
- AsedebartH. Lundbeck A/S · Phase 2
- OMS1620OMass Therapeutics Australia Proprietary Ltd · Phase 1
Coming up1
- 16 Mar 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 16 Mar 2028 | Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026